ClinicalTrials.gg
CompletedNCT06375668Updated Mar 12, 2026

The Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women

An interventional study of Probiotic and Placebo in Osteoporosis, Postmenopausal and Bone Density, Low, sponsored by Nordic Biotic Sp. z o.o.. Completed at 3 sites in Poland. Open to female participants. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Nordic Biotic Sp. z o.o. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Mar 2022, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Osteoporosis, Postmenopausal with a site in Poland — none open to participants now, 2 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · Poland.

Enrollment
34th of 36
170 · median 543
Started
2022
with 3 others
No phase
2 of 36
none open now
Registered
35th of 36
by date

Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, this one is the 34th largest by enrollment, is one of 4 that started in 2022, is one of 2 with no phase, and was the 35th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

None of the 36 studies in Osteoporosis, Postmenopausal with a site in Poland is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Osteoporosis, Postmenopausal with a site in Poland as a file.
02

Study summary

Osteoporosis is a systemic condition characterized by low bone mass and altered bone tissue microarchitecture, with the resulting greater bone fragility leading to fractures. Osteoporosis develops as a result of genetic and environmental factors, with the patient's lifestyle playing an important role. Recent years saw an emergence of reports on the significance of the intestinal microbiota in the development of osteoporosis, thus new ways of modifying the composition and activity of microbiota have been sought, and the potential role of probiotics has been considered. Probiotics are defined as live microorganisms, which-when administered at appropriate doses-are beneficial to the host's health. Probiotics both modify the gut microbiota composition and directly affect the human body. Recently published clinical studies demonstrated that probiotics may facilitate osteoporosis treatment and prevention. The current randomized double-blind placebo-controlled study will assess the effect of a dietary intervention via oral supplementation of Lactobacillus plantarum and Lactobacillus paracasei in a population of Polish postmenopausal women on their bone mineral density assessed via bone densitometry-derived T-scores of the lumbar segment of the spine (L1-L4). Study subjects will take the provided probiotic formulation/placebo orally once daily for 12 months.

Read the detailed description

The main purpose of the study is to assess the effect of oral probiotic supplementation on bone mineral density in postmenopausal women. A total of 170 female subjects who meet all the inclusion criteria and none of the exclusion criteria are to be included and randomized to one of two arms (the probiotic arm or the placebo arm) at a ratio of 1:1.

The subjects who provide their written informed consent will receive oral probiotic formulation containing a mixture of two strains Lactobacillus plantarum and Lactobacillus paracasei or placebo. The probiotic formulation and placebo will be provided by Nordic Biotic Ltd. (the company will also ensure study drug blinding). Study subjects will take the provided probiotic formulation/placebo orally once daily for 12 months.

The study timeline spans 54 weeks and involves 13 visits, including:

  1. Screening visit - subjects eligibility to participate in the study will be assessed based on the inclusion/exclusion criteria - the screening period will last up to 14 before the study drug is administered;
  2. Randomization visit (visit 0) - subjects will be randomly allocated to study groups and will receive a supply of the study probiotic or placebo;
  3. 6 office visits (at months 2, 4, 6, 8, 10, and 12 of visit 0);
  4. 5 remote visits (at months 1, 3, 7, 9, and 11 of visit 0).

All subjects included in the study will undergo:

  • History-taking and physical examination at each office visit,
  • Nutritional status assessment (measurements of body weight and height, with a BMI calculation) at the screening visit and at months 6 and 12 of the study intervention,
  • Two densitometry scans (DEXA) of the lumbar segment of the spine (L1-L4) at the screening visit and at month 12 of visit 0,
  • Treatment satisfaction assessment (treatment satisfaction questionnaire) at months 2, 6, 10, and 12 of the study intervention.

At each visit, whether conducted at the doctor's office or remotely, subjects will be asked about their use of the study drug and any gastrointestinal symptoms (number of bowel movements, stool consistency, bloating, abdominal pain), and the use of any other medications (including antibiotics). Each time, the subjects will be also asked about any side effects. Stool consistency will be assessed with the Bristol Stool Form Scale, and abdominal pain, bloating, and nausea will be assessed with a 5-grade Likert scale.

Blood samples will be collected from all subjects during the screening period, after 6 months of intervention and at the completion of intervention (i.e. at month 12).

The following blood tests will be conducted:

  1. Complete blood count, erythrocyte sedimentation rate, and C-reactive protein levels (at screening and at months 6 and 12 of the study intervention);
  2. Serum calcium, phosphorus, and alkaline phosphatase levels (at screening and at months 6 and 12 of the study intervention);
  3. Serum vitamin D and parathormone levels (at screening and at month 12 of intervention).
03

Conditions studied

  • Osteoporosis, Postmenopausal
  • Bone Density, Low

Keywords

  • bone mineral density
  • osteoporosis
  • probiotics
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women (between 2 and 5 years after their last menstrual period)
  2. A dual-energy X-ray absorptiometry (DEXA) scan-based T-score of the lumbar spine (L1-L4) of less than -1.49 (i.e. a normal value according to the World Health Organization)
  3. (BMI) between 18 and 30
  4. Vitamin 25 (OH)D levels between 31-50 ng/mL

Exclusion criteria

Exclusion Criteria:

  1. The last menstrual period less than 2 or more than 5 years before study recruitment
  2. under 18 or above 30
  3. Oral or transdermal hormone therapy with estrogens and/or progestogens within the last 6 months
  4. or thyroid hormone therapy within the last 6 months
  5. History of osteopenia or osteoporosis
  6. Neoplastic disease treated with cytostatic agents within the last 12 months
  7. disorders, including rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis; malabsorption syndromes, including celiac disease; chronic kidney disease; chronic liver failure; endocrine disorders, including Hashimoto thyroiditis, Graves' disease, Cushing disease or syndrome, hyperparathyroidism, hypogonadism, hyperprolactinemia, acromegaly, diabetes mellitus; and other chronic conditions affecting bone metabolism
  8. Antibiotic therapy within the last 2 months prior to study recruitment
  9. Probiotic use within the last 2 months prior to study recruitment
  10. Calcium and vitamin D supplementation within the 2 months prior to study recruitment
  11. Treatment with antidepressant or antipsychotic agents involving a change of the agents or dosage within the last 3 months
  12. Substance use disorder (alcohol, drugs, nicotine)
  13. History of organ transplantation
  14. Exposure to the SARS-Cov-2 virus within 14 days prior to study recruitment (based on patient declaration)
  15. An acute COVID-19 infection within 14 days prior to study recruitment (based on patient declaration)
  16. A surgical procedure scheduled to take place during this study
  17. Participation in another study within the last 6 months
  18. Inability to give an in writing
  19. Any disease or circumstances that, according to the Investigator or Sponsor, might prevent the subject from completing the study or following study procedures and requirements
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
170 participants (actual)

Study arms

  • Active comparator
    Probiotic

    A dietary supplement in the form of capsules containing probiotic bacterial strains.

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo

    Placebo capsules with the same appearance and weight as probiotic capsules.

    Other: Placebo

Interventions

  • Dietary supplementProbiotic

    The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).

  • OtherPlacebo

    The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.

06

What researchers measure

Primary outcomes

  1. The effect of intervention on bone mineral density

    Bone mineral density (BMD) of the lumbar segment of the spine (L1-L4) will be measured by two densitometry scans (DEXA) and presented as T-score. T-score is measured in standard deviations and reflects the difference between the patient's measured BMD and the mean value of BMD in healthy, young, matched controls (30-year-old women).

    Time frame: From baseline and after 12 months of intervention

Secondary outcomes

  1. Changes in the level of calcium

    The level of calcium will be measured in serum and expressed in mg/dL.

    Time frame: From baseline and after 6 and 12 months of intervention

  2. Changes in the level of phosphorus

    The level of phosphorus will be measured in serum and expressed in mg/dL.

    Time frame: From baseline and after 6 and 12 months of intervention

  3. Changes in the level of alkaline phosphatase

    The level of alkaline phosphatase will be measured in serum and expressed in U/L.

    Time frame: From baseline and after 6 and 12 months of intervention

  4. Changes in the level of vitamin D

    The level of vitamin D will be measured in serum and expressed in ng/mL.

    Time frame: From baseline and after 12 months of intervention

  5. Changes in the level of C-reactive protein

    The level of C-reactive protein will be measured in serum and expressed in mg/L.

    Time frame: From baseline and after 6 and 12 months of intervention

  6. Changes in Body Mass Index (BMI)

    Weight and height will be combined to report BMI in kg/m2.

    Time frame: From baseline and after 6 and 12 months of intervention

  7. Changes in type of stools

    The stool type will be assessed with the Bristol Stool Formation Scale. The Bristol Stool Formation Scale is designed to classify faeces into seven groups: type 1-2 indicate constipation, type 3-4 are "normal" stools; type 5-7 indicate diarrhea.

    Time frame: From baseline for 12 months of intervention in 1 month intervals

  8. Changes in the number of bowel movements

    The number of bowel movements per day will be assessed as mean of bowel movements during the last 7 days before visit.

    Time frame: From baseline for 12 months of intervention in 1 month intervals

  9. Changes in severity of abdominal pain

    The severity of pain will be assessed with a patient-defined 5 point Linkert scale: point 0 - no pain, and 1-4 the severity of pain with higher scores indicating worse pain.

    Time frame: From baseline for 12 months of intervention in 1 month intervals

  10. Changes in severity of bloating

    The bloating will be assessed with a patient-defined 5 point Linkert scale: point 0 - no bloating, and 1-4 the severity of bloating with higher scores indicating worse bloating.

    Time frame: From baseline for 12 months of intervention in 1 month intervals

  11. Occurrence of adverse events

    Adverse events will be recorded and described throughout the intervention period

    Time frame: For 12 months of intervention in 1 month intervals

  12. Satisfaction with the intervention

    Satisfaction with the intervention will be assessed by a questionnaire consisting of 6 questions regarding satisfaction with the form of the preparation, ease of administration, benefits, and course of treatment on a scale of 1-7, with the higher the score, the higher the satisfaction.

    Time frame: At months 2, 6, 10, and 12 of the intervention

07

Study locations

3 sites
  • Private Specialist Practice
    Bytom, 41-902, Poland
  • Specialist Practice
    Katowice, 40-750, Poland
  • Clinical Research Center
    Poznan, 60-773, Poland
08

References and documents

Publications

  • Glogowska-Szelag J, Palka-Kisielowska I, Porawska W, Bierla JB, Szczepankowska AK, Aleksandrzak-Piekarczyk T, Cukrowska B. The Effect of Lacticaseibacillus paracasei LPC100 and Lactiplantibacillus plantarum LP140 on Bone Mineral Density in Postmenopausal Women: A Multicenter, Randomized, Placebo-Controlled Study. J Clin Med. 2024 Oct 8;13(19):5977. doi: 10.3390/jcm13195977. PubMed 39408038 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jan 2024, 22 months.

Of 51 interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 19, 2024
StartActual
Mar 15, 2022
Primary completionActual
Jan 15, 2024
CompletionActual
Jun 15, 2024
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06375668
Lead sponsor
Nordic Biotic Sp. z o.o.
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
Mar 15, 2022
Primary completion
Jan 15, 2024
Completion
Jun 15, 2024
Last update
Mar 12, 2026

Study contacts

Joanna Głogowska-Szeląg, MD, PhD
principal investigator · Private Specialist Practice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion